Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-bl
about
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.The role of IL 23 in the treatment of psoriasis.Chronic Pruritus: Current and Emerging Treatment Options.The role of IL-17 in the treatment of psoriatic arthritis.Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial.IL-23 and Th17 Disease in Inflammatory ArthritisMonoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.Psoriasis pathogenesis and the development of novel targeted immune therapies.Old and New Biological Therapies for Psoriasis.Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis.Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis.Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.Shifting the Focus: The Primary Role of IL-23 in Psoriasis and other Inflammatory Disorders.Guselkumab for psoriasis: a critical appraisal of Phase III studies.Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.Antibodies to watch in 2018.Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.Targeting IL-23 in psoriasis: current perspectives.
P2860
Q38557350-F9E9F2B9-10F4-498A-892B-90942EA47A15Q38645111-83200E2D-F059-4EA9-884C-A5629827E811Q38698960-7CADF327-4416-402C-8689-6D664D48985DQ38707588-28EA43A3-1F6B-420F-AF0F-C7021E989E83Q38976762-3030787B-5C3C-4B4E-BB6F-2B465BC9ABCDQ39156148-8FA1FB90-5105-4C46-A9EE-D1ACA218EC4DQ39293096-9BF79673-4689-4346-965B-803454374C8CQ40164172-3AEB3941-A7A3-4207-B557-CF990FDBB96BQ41674783-F3A9B44A-2C9A-4099-B2C8-8BD0AD48472AQ45977850-FE6F8206-458A-4F88-BCC5-2CF8B2A507D1Q46247849-31B88E0C-B915-4FFC-B7F1-04B00ABB0343Q46506676-1278C0E2-8E53-466C-8B95-6DA216E16B80Q47210888-19217F18-CBC9-4D79-9E34-D3574D5F3220Q47260366-CD65BE33-293F-4F32-997A-403426BE1BCCQ47602117-CBD62C5C-0A89-4927-A63F-D9437B4395D6Q47644680-B3FC5BF1-0AAE-4ECB-A744-02C668842041Q47657450-BBFACAE8-E8D7-4056-B354-1F5520E95534Q47727612-E300D8D7-A401-48F4-862D-5D86B21980DFQ47830025-57615F3D-0D67-47BF-AB6C-AA503BB8AC86Q47859049-0F360E23-61F3-4738-AFBA-3BD70E93CFD3Q47937410-1904AF29-94A7-4249-8DA5-07B924CA9381Q48089393-14DC93C8-1C93-4551-B69E-A64986782BBAQ48104953-B33ACCFF-BFFE-4715-8C87-6A670B51DD32Q48116570-0D9C29E1-2EF9-4F6E-A1E6-060F57ECA7D1Q48132042-67DE62AC-7ACD-4A4C-B1E4-C4B8B9B32859Q48148751-29D0770B-89A8-4E94-96FF-4F60759885B6Q48170767-A9454436-F3F1-4C02-B5A0-A0927D13FDADQ48326905-6DCB35A5-8C8C-4AF0-8F45-6DFE7961C30BQ49210038-88E7B2D2-D410-40E9-9120-2C542A9A1A94Q49276761-A83BE299-D497-46C3-8F84-321238C2D8A7Q49963125-F3747251-A8E0-46D6-859F-F369A9FF9772Q50009848-A1846244-4D8F-40B6-B872-25B21AD1542DQ50034719-C44A26F2-BAD8-43F5-B0DE-EBE2AF68CBA3Q50041283-DBA64031-2AAE-4178-8BF1-13AE56F47EC1Q50086883-5CFF99FF-C8B5-41A1-9705-7BFBDA03674CQ50099588-5EF3866A-CF4B-49FD-A98F-E462AE3A1FC5Q50120289-39AB4866-3C59-4759-8384-1FCB178FDDB0Q50126864-1D71F951-2D76-4A65-8226-AAA497B76E9AQ52670394-7FE4C51D-6ECA-4189-9745-722A19C47BA2Q52695350-38FD475B-6E0D-4A4B-9835-FD5D5941C1A4
P2860
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-bl
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Efficacy and safety of guselku ...... from the phase III, double-bl
@en
type
label
Efficacy and safety of guselku ...... from the phase III, double-bl
@en
prefLabel
Efficacy and safety of guselku ...... from the phase III, double-bl
@en
P2093
P921
P1476
Efficacy and safety of guselku ...... from the phase III, double-bl
@en
P2093
April W Armstrong
Bruce Randazzo
Kenneth B Gordon
Kristian Reich
Michael Song
Peter Foley
Yasmine Wasfi
P304
P356
10.1016/J.JAAD.2016.11.042
P407
P577
2016-12-29T00:00:00Z